Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.2
4.6
Journals
Antibiotics
Special Issues
Multidrug-Resistant Microorganisms: Overcoming the Challenges in Antibiotic Treatment
share announcement

Multidrug-Resistant Microorganisms: Overcoming the Challenges in Antibiotic Treatment

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: 31 December 2026 | Viewed by 836

Special Issue Editors

Dr. Eleni E. Mylona

E-Mail
Guest Editor
Fifth Department of Internal Medicine and Infectious Diseases, Evaggelismos General Hospital, 10676 Athens, Greece
Interests: antimicrobial resistance; infectious diseases in immunocompromised patients; infections in patients with implanted foreign materials; antibiotic stewardship and infection control
Special Issues, Collections and Topics in MDPI journals
Dr. Dimitris Kounatidis

E-Mail
Guest Editor
Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
Interests: diabetes; lipids; biomarkers; lipoproteins; obesity; microbiota; sepsis; antibiotics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The global rise in multidrug-resistant (MDR) microorganisms pose one of the most critical challenges in modern medicine, compromising the effectiveness of conventional antibiotic therapies and threatening patient outcomes. This Special Issue, titled “Multidrug-Resistant Microorganisms: Overcoming the Challenges in Antibiotic Treatment,” provides a comprehensive platform for cutting-edge research on the mechanisms, detection, and therapeutic strategies targeting MDR pathogens. By bridging fundamental research with translational applications, this collection aims to advance our understanding of microbial resistance evolution and to inspire the development of innovative and effective interventions. Ultimately, this Special Issue highlights the urgent need for multidisciplinary collaboration to safeguard the future of infectious disease management and global public health.

We invite submissions that present innovative strategies to combat antimicrobial resistance, including the development of novel antimicrobial agents, combination therapies, phage-based interventions, immunomodulatory approaches, and advanced diagnostic technologies. Contributions may include original research or comprehensive reviews that advance these themes and support the global effort to understand, prevent, and overcome MDR microorganisms.

You may choose our Joint Special Issue in Biomolecules.

Dr. Eleni E. Mylona
Dr. Dimitris Kounatidis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multidrug-resistant
  • antibiotic treatment
  • MDR pathogens
  • therapeutic strategies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

22 pages, 3682 KB  
Article
A Seven-Year Study of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections in a Tertiary Hospital in Greece: A Shift Toward Metallo-β-Lactamase and Dual Carbapenemase Strains
by Eleni Mylona, Sofia Kostourou, Dimitroula Giankoula, Chrysoula Kolokotroni, Paraskevas Tsilikis, Nikolaos Koudoumnakis, Maria Papagianni, Dimitris Kounatidis, Natalia Vallianou, Efstathia Perivolioti and Vasileios Papastamopoulos
Antibiotics 2026, 15(5), 491; https://doi.org/10.3390/antibiotics15050491 - 13 May 2026
Viewed by 454
Abstract
Background/Objectives: Carbapenem-resistant Klebsiella pneumoniae (CRKp) remains a critical driver of antimicrobial resistance (AMR) in hospital settings worldwide. Methods: This study examined trends in CRKp bloodstream infections over a seven-year period (2019–2025) in a tertiary care hospital in Greece, with particular attention given to [...] Read more.
Background/Objectives: Carbapenem-resistant Klebsiella pneumoniae (CRKp) remains a critical driver of antimicrobial resistance (AMR) in hospital settings worldwide. Methods: This study examined trends in CRKp bloodstream infections over a seven-year period (2019–2025) in a tertiary care hospital in Greece, with particular attention given to resistance patterns and patient outcomes, including the impact of the COVID-19 pandemic. Results: A total of 671 non-duplicate CRKp isolates were analyzed and classified into three groups: KPC producers (67.4%), dual carbapenemase producers (dual CP) (17.4%), and single metallo-β-lactamase (MBL) producers (15.2%). Overall incidence showed a slight but non-significant increase over time. KPC-producing strains rose significantly until 2022 (p < 0.001), followed by a marked decline (p < 0.001). In contrast, dual CPs—mainly KPC combined with VIM or NDM—and single-MBL producers, particularly NDM, increased steadily, indicating a notable epidemiological shift. Resistance to aminoglycosides and tigecycline increased around 2021, followed by partial declines, whereas colistin resistance demonstrated a continuous upward trend throughout the study period. Despite phenotypic differences, overall mortality remained high, with no statistically significant differences between groups (p = 0.37), likely reflecting either the severity of patients’ clinical condition or inadequate empirical antibiotic therapy. Conclusions: This study highlights a dynamic evolution in CRKp epidemiology with decreasing KPC dominance and increasing prevalence of MBL- and dual CP strains. This transition, which became evident during and after the COVID-19 pandemic, underscores ongoing epidemiological adaptation and the urgent need for improved antimicrobial stewardship, rapid diagnostics, and broader access to effective therapies. Full article
(This article belongs to the Special Issue Multidrug-Resistant Microorganisms: Overcoming the Challenges in Antibiotic Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop